On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read More
Viz.ai and Alnylam Forge Strategic Alliance to Revolutionize Cardiac Amyloidosis Diagnosis and Care
In a significant development poised to reshape the landscape of cardiovascular medicine, Viz.ai has announced a groundbreaking collaboration with Alnylam…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
The Rise of AI-Driven Autonomous Laboratories: Reshaping Pharmaceutical R&D
The landscape of pharmaceutical research and development (R&D) is undergoing a profound transformation, driven by the increasing integration of artificial…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
Monash University and ClinChoice Forge Strategic Alliance to Accelerate Therapeutic Development and Enhance Patient Access to Novel Treatments
Australia’s Monash University, a leading research institution, and ClinChoice, a global contract research organization (CRO), have formally announced a significant…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read More
Accelerated Pathways: A Strategic Approach to Fast-Track Qualifications in Today’s Dynamic Career Landscape
Before choosing a fast-track qualification, you should consider the workload, outcome, and more. The modern professional landscape is characterized by…
Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult Populations
Bristol Myers Squibb’s (BMS) groundbreaking immunotherapy, Opdivo (nivolumab), has achieved a significant milestone with dual approvals from the U.S. Food…
Read More
Macau Approves ImmunityBio’s Anktiva for Bladder Cancer, Marking First Asian Regulatory Milestone
ImmunityBio has achieved a significant regulatory victory with the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China,…
Read More
